Vu Quan Anh 4

What Happened

• Vu Quan Anh, Chief Financial Officer of Monopar Therapeutics (MNPR), had 1,228 restricted stock units (RSUs vest) converted into common shares on June 30, 2026. To cover withholding taxes, 507 of those shares were surrendered to the issuer for tax payment (reported value $92.59/share; $46,943 total). The net result was an increase of 721 shares to his holdings.
• This was an award/vesting transaction (not an open-market buy or sale). The gross value of the 1,228 vested shares at $92.59 was about $113,701 before tax withholding.

Key Details

• Transaction date: 2026-06-30 (Form filed 2026-07-02).
• Vesting/conversion: 1,228 RSUs converted to 1,228 common shares (derivative exercise/settlement).
• Tax withholding: 507 shares withheld at $92.59/share for $46,943 (code F — tax payment).
• Net shares received: 721 shares (1,228 − 507), approx. $66,757 at $92.59/share.
• Shares owned after transaction: Not disclosed in this Form 4.
• Footnotes: The shares came from a Dec 2, 2025 grant of 9,826 RSUs vesting 6/48ths (1,228) on 6/30/2026 and 614 shares every three months thereafter through 12/31/2029. Withheld shares were surrendered to cover tax withholding upon vesting.

Context

• This was a routine vesting/settlement of RSUs with shares withheld to satisfy tax obligations (a common practice that does not indicate an open-market sale or purchase).
• No 10b5-1 or gift indication; not an exercise-for-sale—shares were not sold on the open market.